A new orally active insulin-mimetic vanadyl complex: bis(pyrrolidine-N-carbodithioato)oxovanadium(IV)

1994 ◽  
Vol 37 (7) ◽  
pp. 876-877 ◽  
Author(s):  
Hiromi Watanabe ◽  
Masami Nakai ◽  
Kyoko Komazawa ◽  
Hiromu Sakurai
Keyword(s):  
Insulin Mimetic ◽  
Vanadyl Complex ◽  
Orally Active

A New Type of Orally Active Insulin-Mimetic Vanadyl Complex: Bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) with VO(S2O2) Coordination Mode

1999 ◽  
Vol 28 (9) ◽  
pp. 913-914 ◽  
Author(s):  
Hiromu Sakurai ◽  
Hiromi Sano ◽  
Toshikazu Takino ◽  
Hiroyuki Yasui
Keyword(s):  
Coordination Mode ◽  
Insulin Mimetic ◽  
Vanadyl Complex ◽  
New Type ◽  
Orally Active

Total Syntheses of Demethylasterriquinone B1, an Orally Active Insulin Mimetic, and Demethylasterriquinone A1

2002 ◽  
Vol 67 (23) ◽  
pp. 7919-7926 ◽  
Author(s):  
Michael C. Pirrung ◽  
Zhitao Li ◽  
Kaapjoo Park ◽  
Jin Zhu
Keyword(s):  
Total Syntheses ◽  
Insulin Mimetic ◽  
Orally Active ◽  
Demethylasterriquinone B1

A new orally active antidiabetic vanadyl complex – bis(α-furancarboxylato)oxovanadium(IV)

2005 ◽  
Vol 99 (2) ◽  
pp. 546-551 ◽  
Author(s):  
Mingjin Xie ◽  
Lihui Gao ◽  
Ling Li ◽  
Weiping Liu ◽  
Shiping Yan
Keyword(s):  
Vanadyl Complex ◽  
Orally Active

A New Type of Orally Active Insulin-mimetic Vanadyl-porphyrin Complex:meso-Tetrakis({4-sulfonatophenyl}porphyrinato)oxovanadium(IV)

2005 ◽  
Vol 34 (10) ◽  
pp. 1350-1351 ◽  
Author(s):  
Tapan Kumar Saha ◽  
Yusuke Adachi ◽  
Yutaka Yoshikawa ◽  
Hiroyuki Yasui ◽  
Hiromu Sakurai
Keyword(s):  
Insulin Mimetic ◽  
Vanadyl Porphyrin ◽  
New Type ◽  
Orally Active

Molecular Docking Studies and Pharmacophore Modeling of Some Insulin Mimetic Agents from Herbal Sources: A Rational Approach towards Designing of Orally Active Insulin Mimetic Agents

2020 ◽  
Vol 6 (2) ◽  
pp. 121-133
Author(s):  
Joohee Pradhan ◽  
Sunita Panchawat
Keyword(s):  
Hydrogen Bond ◽  
Insulin Receptor ◽  
Pharmacophore Modeling ◽  
Rational Approach ◽  
Oral Insulin ◽  
Hydrogen Bond Acceptor ◽  
Insulin Receptor Tyrosine Kinase ◽  
Lipinski’S Rule ◽  
Insulin Mimetic ◽  
Orally Active

Background:: Many herbal drugs have been found to possess oral insulin mimetic property as evidenced from the literature. Although, to date there is no efficient, synthetic orally active insulin-mimetic drug available clinically. Computer-Aided Drug Design (CADD) may help in the development of such agents through Pharmacophore modeling. Objective:: The present work is aimed at the In-silico designing of Pharmacophore that defines the structural requirements of a molecule to possess oral insulin-mimetic properties. Methods:: A set of 16 orally active insulin-mimetic natural compounds available through literature was used to develop a structure-based pharmacophore in a “three-step filtration process” comprised of Lipinski’s rule of 5, Minimum binding energy with the receptor and Ghose filter to the Lipinski’s rule for oral bioavailability of the drugs. The selected ligands were docked with phosphorylated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog (PDB ID: 1IR3) using Autodock 4.2 and their interaction with the receptor was analyzed followed by the generation of shared and merged feature pharmacophore by Ligandscout 4.2.1. Results:: There are three important structural features that contribute to interaction with the active site of the insulin receptor: these are hydrogen bond donor groups, hydrogen bond acceptor groups and hydrophobic interactions. It is important to note that positive or negative ionizable groups or the presence of aromatic rings are not important for the activity. Conclusion:: Taking a clue from the developed pharmacophore, one may design new lead having necessary groups required for the insulin-mimetic activity that can be elaborated synthetically to get a series of compounds with possible oral insulin-mimetic activity.

Sign in / Sign up

Export Citation Format

Share Document